Bank of New York Mellon Corp grew its holdings in Syneos Health Inc (NASDAQ:SYNH) by 4.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 652,958 shares of the company’s stock after buying an additional 26,267 shares during the period. Bank of New York Mellon Corp owned approximately 0.63% of Syneos Health worth $30,623,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also modified their holdings of the business. BlackRock Inc. grew its stake in shares of Syneos Health by 3.0% in the 2nd quarter. BlackRock Inc. now owns 7,284,876 shares of the company’s stock worth $341,662,000 after buying an additional 213,185 shares in the last quarter. Boston Partners grew its stake in shares of Syneos Health by 4.0% in the 2nd quarter. Boston Partners now owns 733,156 shares of the company’s stock worth $34,385,000 after buying an additional 28,205 shares in the last quarter. Principal Financial Group Inc. purchased a new position in shares of Syneos Health in the 1st quarter worth $25,497,000. Point72 Asset Management L.P. grew its stake in shares of Syneos Health by 6.7% in the 2nd quarter. Point72 Asset Management L.P. now owns 530,800 shares of the company’s stock worth $24,895,000 after buying an additional 33,200 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Syneos Health by 1.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 497,317 shares of the company’s stock worth $23,324,000 after buying an additional 8,384 shares in the last quarter.
SYNH has been the subject of a number of recent research reports. ValuEngine raised shares of Syneos Health from a “hold” rating to a “buy” rating in a research note on Saturday, November 10th. Zacks Investment Research raised shares of Syneos Health from a “hold” rating to a “buy” rating and set a $56.00 price objective for the company in a research note on Tuesday, November 20th. UBS Group initiated coverage on shares of Syneos Health in a research note on Tuesday, October 9th. They issued a “buy” rating and a $60.00 price objective for the company. SunTrust Banks reissued a “buy” rating and issued a $60.00 price objective on shares of Syneos Health in a research note on Friday, August 3rd. Finally, Mizuho reissued a “hold” rating and issued a $51.00 price objective on shares of Syneos Health in a research note on Monday, August 6th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $54.70.
Syneos Health (NASDAQ:SYNH) last released its earnings results on Tuesday, November 6th. The company reported $0.75 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.58 by $0.17. The firm had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.12 billion. Syneos Health had a negative net margin of 0.84% and a positive return on equity of 8.67%. The company’s revenue for the quarter was up 88.3% compared to the same quarter last year. Research analysts forecast that Syneos Health Inc will post 2.47 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Bank of New York Mellon Corp Acquires 26,267 Shares of Syneos Health Inc (SYNH)” was originally posted by WKRB News and is the property of of WKRB News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.wkrb13.com/2018/11/26/bank-of-new-york-mellon-corp-acquires-26267-shares-of-syneos-health-inc-synh.html.
Syneos Health Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Further Reading: Short Selling
Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health Inc (NASDAQ:SYNH).
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.